Skip to main content

Table 3 Description of patients with virologic failure

From: Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study

Patients with virologic failure n=13

Previous ART (just before switching)

Previous ART duration

VL at failure (copies/mL)

VL confirmation

Time of VF after the switch

Previous VF§

Previous INSTI exposure

Previous genotypic test

Genotypic test at VF

NRTI RAMs

INSTI RAMs

NRTI RAMs

INSTI RAMs

VL>50 copies/mL between W0 and W48 leading to treatment discontinuation

           

 Patient 01

TDF/FTC+ ATV/r

3.7 years

10257

418

1.5 months

Yes

Yes

L74V, M184V

N155H

L74V, M184V

N155H

 Patient 02

TDF/FTC+DRV/r

3 years

65679

110664

5 months

No

No

T215N/Y/S, M184V

ND

L74V, M184V

N155H

 Patient 03

TDF/FTC+DRV/r

3 years

77

180370

3 months

No

No

T215A/C/D/E/G/H

T215I/L/N/S/V

ND

41L,M184V,T215Y

L74F/I,Q148H/R/K

 Patient 04

TDF/FTC+DRV/r

7 months

37791

16041

2 months

Yes

Yes

None

None

NA

NA

VL>50 copies/mL between W0 and W48 without treatment discontinuation (or LTFU)

           

 Patient 05*

TDF/FTC+ ATV/r

8 months

2918

ND

4 months

NA

No

M184V

ND

ND

ND

 Patient 06*

TDF/FTC+DRV/r

1 year

60

112

2 months

NA

No

ND

ND

ND

ND

 Patient 07*

TDF/FTC+DRV/r

2.2 years

112

ND

5 months

NA

No

NA

NA

ND

ND

 Patient 08**

TDF/FTC+RAL

4 years

91

158

6 months

Yes

Yes

NA

NA

ND

ND

Vl>50 copies/mL at W48

           

 Patient 09

TDF/FTC+RAL

2.3 years

453

149

11 months

No

Yes

None

None

No amplification

No amplification

 Patient 10

TDF/FTC+FPV/r

7 years

6830

4990

12 months

Yes

No

D67N, K70R,L74V,M184V/I,T215Y/F, K219Q/E

ND

D67N, K70R,M184V/I,S215F, K219Q/E

N155H

 Patient 11

ABC/3TC+ATV

9 years

169

594

12 months

NA

No

NA

NA

D67N, K70R,M184V/I,K219Q/E

N155H

 Patient 12

TDF/FTC+ ATV/r

9 months

3339

22957

12 months

Yes

No

None

None

None

None

 Patient 13

TDF/FTC/EFV

2.5 years

1767

ND

12 months

Yes

No

None

ND

ND

ND

  1. ART antiretroviral therapy, INSTI integrase strand inhibitor, NRTI nucleoside reverse transcriptase inhibitor, RAM resistance associated mutations, VL viral load, VF virologic failure; NA information not available in the data base, ND not done, LTFU lost to follow-up
  2. TDF/FTC tenofovir/emtricitabine, EFV efavirenz, DRV/r darunavir boosted with ritonavir, ATV atazanavir, ATV/r atazanavir boosted with ritonavir, RAL raltegravir, FPV/r fosamprenavir boosted with ritonavir
  3. §Previous VF based on the mention in the patient’s therapeutic history that ART was changed because of VF
  4. *These patients were lost to follow-up after the diagnosis of VF but patient 7 never stopped treatment and returned to his center in sept 2017 with undetectable HIV RNA while still on E/C/F/TDF
  5. **This patient continued E/C/F/TDF for an additional year but with persistent low levels viraemia. 18 months later, INSTI associated resistance was confirmed and the patient switched to PI/r